STOCK TITAN

Kellanova 8-K Filings

K NYSE

Every 8-K that Kellanova (K) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 8-K covers material events a company has to report between its quarterly reports, so if you follow K and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full K filings page.

Rhea-AI Summary

Kellanova reported that its previously announced merger with Acquiror 10VB8, LLC, an affiliate of Mars, Incorporated, closed on December 11, 2025. Merger Sub 10VB8, LLC was merged into Kellanova, and Kellanova now operates as a wholly owned subsidiary of Acquiror.

At the merger’s effective time, each share of Kellanova common stock (with limited exceptions) was converted into the right to receive $83.50 in cash per share, and all stock options, restricted stock units, performance stock units and deferred stock units were cashed out based on this price and accrued dividend equivalents, with certain retention payments for some performance units.

Following the change of control, Kellanova guaranteed on a senior unsecured basis the Parent’s obligations under its senior credit facilities, private placement notes and senior notes, and terminated and repaid its prior five-year credit facility. The company has requested delisting of its common stock and certain notes from the NYSE and the Luxembourg Stock Exchange and plans to terminate its SEC reporting obligations. The pre-merger board and top officers resigned, and designees of the acquiror were appointed along with amended and restated charter and bylaws.

Rhea-AI Summary

Kellanova announced that Mars, Incorporated has received unconditional approval from the European Commission for their pending merger, meaning all required regulatory clearances for the deal are now in place. The companies intend to close the merger on December 11, 2025, subject to the satisfaction or waiver of the remaining customary closing conditions in their Merger Agreement. After the merger is completed, Kellanova’s common stock will be delisted from the New York Stock Exchange and will no longer be publicly traded, so current shareholders would hold shares in a company that becomes a wholly owned subsidiary of Mars’ acquisition vehicle.

Rhea-AI Summary

Kellanova furnished an 8‑K under Item 2.02 announcing it issued a press release with financial results for the period ended September 27, 2025. The press release is attached as Exhibit 99.1. The company states this information is furnished and not deemed “filed” under Section 18 of the Exchange Act, and is not incorporated by reference except as specifically stated.

8-K
Rhea-AI Summary

Kellanova (NYSE:K) filed a Form 8-K on June 26, 2025, disclosing that the U.S. Federal Trade Commission has completed its antitrust review of Mars’ pending acquisition of the company.

FTC clearance removes the principal U.S. regulatory obstacle and materially increases the likelihood of closing, though the deal still requires customary conditions and any remaining foreign approvals.

  • Disclosure furnished under Item 7.01; no financial statements included.
  • Exhibit 99.1 is the joint Kellanova–Mars press release, deemed “furnished,” not “filed.”
  • Common stock (K) and senior notes (K29, K34) continue to trade on NYSE.
Rhea-AI Summary

Kellanova (NYSE:K) announced that the European Commission has initiated a Phase II investigation into its pending merger with Mars, Incorporated. The merger agreement, originally announced on August 13, 2024, would result in Kellanova becoming a wholly-owned subsidiary of Acquiror 10VB8, LLC. Due to this regulatory review, the merger completion is now expected towards the end of 2025. Despite the extended timeline, both Kellanova and Mars remain optimistic about obtaining European Commission antitrust approval. The transaction remains subject to customary closing conditions and required regulatory approvals.